Kanvas Biosciences

Kanvas Biosciences is building the world's first microbiome drug screening and drug discovery platform to accelerate the development of Live Biotherapeutic Products (LBP). Leveraging its unparalleled capabilities in single-cell resolution microbiome spatial mapping and host gene expression mapping, the company is constructing the most comprehensive and powerful microbiome data resource for future drug development. Kanvas Biosciences' technology was initially developed at Cornell University and has been exclusively licensed. Kanvas’ mission is to revolutionize microbiome research and infectious disease diagnostics using next-generation imaging technology.